Datavault AI (NASDAQ: DVLT) and Wellgistics Health Inc. have signed a non-binding letter of intent to integrate Datavault's blockchain-enabled PharmacyChain(TM) smart contract technology into Wellgistics' pharmaceutical distribution and digital prescription routing infrastructure. The partnership aims to digitize prescription tracking from script to fulfillment, ensuring accurate, transparent and efficient delivery while supporting patient safety and optimized outcomes.
According to the announcement, the companies are exploring a revenue-sharing model based on PharmacyChain(TM) usage fees, with definitive terms to be determined following further negotiation. The full press release is available at https://ibn.fm/dnQ0i.
This collaboration is significant as it addresses a critical challenge in the pharmaceutical supply chain: the lack of end-to-end visibility and traceability of prescription drugs. By leveraging blockchain technology, the partnership aims to create an immutable record of each transaction, reducing the risk of counterfeit drugs, medication errors, and inefficiencies. The integration into Wellgistics' proprietary infrastructure could streamline operations for pharmacies, healthcare providers, and patients, potentially lowering costs and improving health outcomes.
Datavault AI is a leader in AI-driven data experience, valuation, and monetization in the Web 3.0 environment. Its cloud-based platform provides comprehensive solutions across its Acoustic Science and Data Science Divisions. The Data Science Division leverages Web 3.0 and high-performance computing for experiential data perception, valuation, and secure monetization. The Information Data Exchange (IDE) enables Digital Twins and licensing of name, image, and likeness (NIL) by securely attaching physical objects to immutable metadata objects. More information is available at www.datavaultsite.com.
Wellgistics Health is a next-generation pharmaceutical distribution and digital prescription routing company. While specific details about its operations were not disclosed in the release, the partnership suggests a focus on innovation in prescription drug logistics.
The implications of this announcement extend beyond the two companies. If successful, the blockchain-enabled tracking system could set a new standard for prescription drug traceability, potentially influencing regulatory frameworks and industry practices. It also highlights the growing intersection of AI, blockchain, and healthcare, where data security and transparency are paramount.
Forward-looking statements in the release caution that actual results may differ materially due to risks and uncertainties, including those discussed in the company's SEC filings. The full disclaimer is available at http://IBN.fm/Disclaimer.
